<DOC>
	<DOCNO>NCT02321241</DOCNO>
	<brief_summary>The aim TITAN study describe clinical practice cohort patient wAMD refractory ranibizumab ( persistence intra-retinal and/or subretinal fluid ) switch aflibercept less 12 month ranibizumab treatment . The study conduct real-life condition allow describe condition use aflibercept patient refractory ranibizumab</brief_summary>
	<brief_title>Real Life Aflibercept France Patients Refractory Ranibizumab : Observational Study Wet AMD</brief_title>
	<detailed_description>The study retrsopective prospective collect local real life data patient routine treatment . The observation period start January 2014 . Patients initiated treatment Aflibercept 1st january 2014 31 December 2015 enrol .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Man woman &gt; 18 year old Patient wAMD previously treat ranibizumab ( le 12 month initiation Aflibercept ) Refractory ranibizumab ( defined persistent fluid despite treatment conduct accord HAS French recommendation least 3 load dos injection ) Patient switch aflibercept ( Eylea ) 1st January 2014 30th June 2015 Written inform consent give Patient meet local indication criterion aflibercept treatment . Contraindications list local SmPC ( Summary Product Characteristics ) consider Recurrent patient wAMD previously treat ranibizumab switch aflibercept high recurrence rate ( recurrent patient describe Yonegawa et al.in AJO ( American Journal Ophthalmology ) 2013= exudation suppress high rate injection ) Patient previously treat macular laser Visudyne/PD ( Photodynamic therapy ) Patient Visual Acuity ( VA ) &lt; 1/10 Patient Fibrosis involve Macula Patient atrophic AMD Patient retinal disease myopia , diabetic retinopathy , diabetic macular oedema , chorioretinal anastomosis ( CRA ) , , angioid streak Patients take part interventional study time enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Wet-AMD</keyword>
	<keyword>Refractory patient ranibizumab</keyword>
	<keyword>Real life</keyword>
	<keyword>Switch</keyword>
	<keyword>Aflibercept</keyword>
</DOC>